Vimarsana
Biggest News Aggregation in the World

Page 22 - Full Year News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Full Year. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Full Year Today - Breaking & Trending Today

Equity Residential Reports First Quarter 2024 Results - Vimarsana News

Equity Residential Reports First Quarter 2024 Results

Same Store Results Ahead of Expectations ...

Tiendas 3B Announces New Time for Its Full Year and Fourth Quarter 2023 Earnings Conference Call - Vimarsana News

Tiendas 3B Announces New Time for Its Full Year and Fourth Quarter 2023 Earnings Conference Call

BBB Foods Inc. ("Tiendas 3B" or the "Company") announced a change in the scheduling of its upcoming earnings results conference call. The call will still take place on April 26, 2024, but will now be held at 10:00 a.m. ET, instead of the previously...

Mobico Group Plc reports Revenue Growth and Profitability Impact from Inflationary Pressures - Vimarsana News

Mobico Group Plc reports Revenue Growth and Profitability Impact from Inflationary Pressures

Mobico Group PLC (LON:MCG) reports strong revenue growth for FY 2023, driven by passenger volumes and route recovery. Profitability impacted by inflation and Covid support reduction. Adjusted Operating Profit expected at £185-£205m.

Cidara Therapeutics Provides Corporate Update and Reports - Vimarsana News

Cidara Therapeutics Provides Corporate Update and Reports

SAN DIEGO, April 22, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary...

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO, April 22, 2024 -- Cidara Therapeutics, Inc. , a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate immunotherapies designed to save lives...